Summary of Revisions: <i>Standards of Care in Diabetes—2023</i>

ElSayed, Nuha A.; Aroda, Vanita R.; Bannuru, Raveendhara R.; Brown, F. C.; Bruemmer, Dennis; Collins, Billy; Cusi, Kenneth; Das, Sandeep R; Gibbons, Christopher H.; Giurini, John M.; Hilliard, Marisa E.; Isaacs, Diana; Johnson, Eric L.; Kahan, Scott; Khunti, Kamlesh; Kosiborod, Mikhail; Leon, Jose I.; Lyons, Sarah K.; Murdock, Lisa; Perry, Mary Lou; Prahalad, Priya; Pratley, Richard E.; Seley, Jane Jeffrie; Stanton, Robert C.; Sun, Jennifer K.; Woodward, Crystal C.; Young-Hyman, Deborah Lee; Gabbay, Robert A.

doi:10.2337/dc23-srev

Cited by 95 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,9 In patients with diabetes, the American Diabetes Association recommends a target blood pressure lower than 130/80 mm Hg. 10 Most people are not meeting these goals. According to an estimate from the US Centers for Disease Control and Prevention, of the 116 million Americans with hypertension, only 23.9 million (20.6%) have their blood pressure controlled using the 2017 ACC-AHA defi nitions.…”

Section: Yahr and Colleaguesmentioning

confidence: 99%

Resistant hypertension: A stepwise approach

Yahr

Thomas

Calle

et al. 2023

CCJM

View full text Add to dashboard Cite

show abstract

Section: Yahr and Colleaguesmentioning

confidence: 99%

Resistant hypertension: A stepwise approach

Yahr

Thomas

Calle

et al. 2023

CCJM

View full text Add to dashboard Cite

show abstract

“…67 New additions to the 2023 ADA standards of care for CVD and risk management include finerenone as treatment in individuals with T2D and CKD with albuminuria receiving the maximum tolerated doses of ACE inhibitor or ARB (Table 2). 81…”

Section: Updated Guideline Recommendations For the Management Of Pati...mentioning

confidence: 99%

“…The discussion of evidence to support this new recommendation was included in the last paragraph of the section ‘Glucose‐Lowering Therapies and Heart Failure’ (Erratum, summary of revisions) 81 …”

Section: Updated Guideline Recommendations For the Management Of Pati...mentioning

confidence: 99%

“…Summary of revisions in the 2023 ADA Standards of Care 81 : MRAs are now recommended along with other medications for CV and kidney protection rather than as alternatives when other treatments have not been effective…”

Section: Updated Guideline Recommendations For the Management Of Pati...mentioning

confidence: 99%

“…New guidance from the 2023 ADA Standards of Care recommends treatment with an SGLT2 inhibitor in individuals with T2D and established HF with either preserved or reduced ejection fraction to improve symptoms, physical limitations and quality of life. ADA recommendations specifically for people with HF are summarized and outlined in Table 1 81 . The KDIGO guidelines suggest the use of ACE inhibitors or ARBs to reduce blood pressure in patients with T2D and CKD 25 .…”

Section: Updated Guideline Recommendations For the Management Of Pati...mentioning

confidence: 99%

See 2 more Smart Citations

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Bell

McGill

Jerkins³

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Patients with type 2 diabetes are at an increased risk of developing heart failure and chronic kidney disease. The presence of these co‐morbidities substantially increases the risk of morbidity as well as mortality in patients with diabetes. The clinical focus has historically centred around reducing the risk of cardiovascular disease by targeting hyperglycaemia, hyperlipidaemia and hypertension. Nonetheless, patients with type 2 diabetes who have well‐controlled blood glucose, blood pressure and lipid levels may still go on to develop heart failure, kidney disease or both. Major diabetes and cardiovascular societies are now recommending the use of treatments such as sodium‐glucose co‐transporter‐2 inhibitors and non‐steroidal mineralocorticoid receptor antagonists, in addition to currently recommended therapies, to promote cardiorenal protection through alternative pathways as early as possible in individuals with diabetes and cardiorenal manifestations. This review examines the most recent recommendations for managing the risk of cardiorenal progression in patients with type 2 diabetes.

show abstract

Predictive value of valvular calcification for the recurrence of persistent atrial fibrillation after radiofrequency catheter ablation

Liu,

Li,

Long

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundValvular calcification (VC) is an independent risk factor for cardiovascular diseases. The relationship between VC and atrial fibrillation is not clear.HypothesisWe treated the aortic valve, mitral valve, and tricuspid valve as a whole and considered the possible association between VC and recurrence of persistent atrial fibrillation (PsAF) after radiofrequency catheter ablation (RFCA).MethodsThis study involved 2687 PsAF patients who underwent RFCA. Data were collected to explore the relationship between VC and outcome. VC was defined by echocardiography in aortic valve, mitral valve, or tricuspid valve. After 1 year follow‐up, subgroup analysis, mixed model regression analysis, and score system analysis were performed. The external validation of 133 patients demonstrated the accuracy of this clinical prediction model.ResultsOverall, 2687 inpatients were assigned to the recurrence group (n = 682) or the no recurrence group (n = 2005) with or without VC. Compared to patients with no recurrence, the incidence of VC was higher in recurrence patients. Recurrence was present in 18.5%, 34.9%, 39.3%, and 52.0% of the four groups, which met VC numbers of 0, 1, 2, and 3, respectively. After adjustment for potential confounding factors, VC was an independent risk factor for AF recurrence in several models. For multivariable logistic regression, a scoring system was established based on the regression coefficient. The receiver operating characteristic area of the scoring system was 0.787 in the external validation cohort.ConclusionsVC was an independent risk factor for AF recurrence in PsAF after RFCA. The scoring system may be a useful clinical tool to assess AF recurrence.

show abstract

Summary of Revisions: Standards of Care in Diabetes—2023

Cited by 95 publications

References 0 publications

Resistant hypertension: A stepwise approach

Resistant hypertension: A stepwise approach

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Predictive value of valvular calcification for the recurrence of persistent atrial fibrillation after radiofrequency catheter ablation

Contact Info

Product

Resources

About